Omid Hamid, MD
Talimogene laherparepvec (T-VEC; Imlygic) was approved by the FDA in 2015 for the treatment of patients with locally advanced, unresectable melanoma and has since continued to show durable responses and minimal toxicity as a single agent and in combination with checkpoint inhibitors, making it a worthwhile treatment strategy to explore further, explained Omid Hamid, MD.
“Oncolytic viruses have already been approved in China for head and neck cancer. They’re a great way to prime the immune system,” said Hamid, director of Research and Immuno-Oncology at The Angeles Clinic. “They're not checkpoint inhibitors, so you can prime with the virus and boost with a checkpoint [inhibitor]. They've shown very little toxicity. Oncolytic viruses show a significant benefit that warrant future study.”
... to read the full story